GOLDLINE PHARMACEU...● IPO DETAIL GMP+₹26 STATUSListed IPOCloudTrack Every IPO GOLDLINE PHARMACEU...● IPO DETAIL GMP+₹26 STATUSListed IPOCloudTrack Every IPO
Live GMP
Back to IPOs
Goldline Pharmaceutical Ltd.

Goldline Pharmaceutical Ltd.

BSE SME · SME IPO
Listed BSE SME SME Live Chart
Issue Price
₹43
₹43
GMP (Grey Market)
+₹26
+60.47%
Est. Listing Price
₹69
Based on GMP
Min. Investment
₹129,000
1 lot × 3000 shares
Subscribed
598.69x
Over-subscribed
IPO Details
Open Date
12 May 2026
Close Date
14 May 2026
Allotment
15 May 2026
Listing Date
19 May 2026
Exchange
BSE SME
Price Band
₹43
Listing Price
See chart
Allotment Status
Price Band
₹43
Per share
Face Value
₹10 per share
 
Lot Size
3,000 Shares
per lot
Issue Size
27,00,000 shares (agg. up to ₹12 Cr)
Total offering
Issue Type
Bookbuilding IPO
 
Min Investment
₹129,000
1 lot
Pre-IPO Holding
69,00,000 shares
Promoters
Post-IPO Holding
96,00,000 shares
Promoters
UPI Deadline
5:00 PM on 14 May 2026
Mandate
GMP
+₹26
+60.47% est.
Anchor AllotmentMon, 11 May 2026
Basis of AllotmentFri, 15 May 2026
Refund InitiationMon, 18 May 2026
Demat CreditMon, 18 May 2026
Listing DayTue, 19 May 2026
UPI Mandate Deadline5:00 PM on 14 May 2026
Sale TypeFresh capital only
Net Offer to Public25,62,000 shares (agg. up to ₹11 Cr)
Market Maker Quota1,38,000 shares (agg. up to ₹0.5934 Cr)
Fresh Issue Shares25,62,000 shares (agg. up to ₹11 Cr)
QIB Quota50% of Net Issue
HNI / NII Quota15% of Net Issue
Retail Quota35% of Net Issue
Check AllotmentClick here →
Subscription Rate Final
Goldline Pharmaceutical Ltd. IPO subscribed 598.69 times overall. Retail: 874.20x. QIB: 76.99x. NII: 1,664.45x. By 14 May 2026.
QIB
76.99x
Over
NII/HNI
1,664.45x
Over
Retail
874.20x
Over
Total
598.69x
Over
Category Subscription Shares Offered % of Total Amount (₹Cr)
Market Maker
Awaited
138,000
₹0.59
QIB
Over 76.99x
1,272,000
₹5.47
NII / HNI
Over 1,664.45x
390,000
₹1.68
Retail
Over 874.20x
900,000
₹3.87
Total 598.69x
2,562,000
100% ₹11.02
IPO Shares Offered
Goldline Pharmaceutical Ltd. IPO total issue size: ₹11.02 Cr. Retail: ₹3.87 Cr. QIB: ₹5.47 Cr. NII: ₹1.68 Cr.
CategoryShares OfferedAmount (₹Cr)Size (%)
QIB 1,272,000 ₹5.47
49.65%
Market Maker 138,000 ₹0.59
5.39%
NII 390,000 ₹1.68
15.22%
Retail 900,000 ₹3.87
35.13%
Total 2,562,000 ₹11.02
100.00%
* Based on upper price band ₹43 per share
Basis of Allotment
QIB NII Retail Total
Ex. Anchor Anchor Total QIB Below ₹10L Above ₹10L Total NII
Allocation (shares) 390,000 900,000 1,290,000
Allotment price (₹) 43 43 43 43 43 43 43 43
No. of applications
No. of shares applied
Amount collected (₹Cr) ₹3.87 ₹3.87
Times subscribed 76.99x 1,664.45x 874.20x 598.69x
Shares allotted 390,000 900,000 1,290,000
No. of allottees
* Upper price band ₹43 · ** Anchor allotment excluded from public shares
Lot Size & Investment
Lot Size
3,000
Shares per Lot
Issue Price
₹43.00
Upper Band
Min Investment
₹129,000
1 Lot
ApplicationLotsSharesAmount
Retail (Min — 2 Lots)26,000₹258,000
Retail (Max — 13 Lots)1339,000₹1,677,000
S-HNI (Min — 14 Lots)1442,000₹1,806,000
B-HNI (Min — 68 Lots)68204,000₹8,772,000
* Issue Price ₹43 × Lot Size 3,000 shares
IPO Schedule
Anchor
11 May 2026
✓ Done
IPO Open
12 May 2026
✓ Done
IPO Close
14 May 2026
✓ Done
Allotment
15 May 2026
✓ Done
Refunds
18 May 2026
✓ Done
Demat Credit
18 May 2026
✓ Done
Listing Day
19 May 2026
✓ Done
Goldline Pharmaceutical Ltd. — Live Price LIVE
₹43.00
INR · BSE
Fetching…
vs Issue Price
OPEN
HIGH
LOW
MKT CAP
P/E
52W HIGH
52W LOW
VOLUME
DIVIDEND
DIV YIELD
Loading…
Chart Not Available
Try again 2–3 days after listing.
Issue ₹43.00 GMP: +₹26 Live Price
About Goldline Pharmaceutical Ltd.
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners.Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians.Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy.The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.Competitive Strengths:Experienced Promoters and Management Team with Industry Knowledge and a Track RecordAsset-light Business Model and Competitive ProductsScalable Business ModelWide and Diverse Range of Product OfferingsStrong Supplier and Vendor RelationshipsEstablished Distribution Network
Objects of the Issue
1
Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company
2
General corporate purposes
Goldline Pharmaceutical Ltd. Financials (Amount in ₹ Crore)
Revenue from Operations
₹19.9
31 Mar 2023
₹23.6
31 Mar 2024
₹28.1
31 Mar 2025
Profit After Tax (PAT)
₹0.3
31 Mar 2023
₹1.8
31 Mar 2024
₹2.8
31 Mar 2025
Particulars31 Mar 202531 Mar 202431 Mar 2023
Revenue from Operations 28.06 23.57 19.85
EBITDA 5.83 4.30 2.19
Profit After Tax (PAT) 2.83 1.81 0.26
Net Worth 10.35 7.87 5.89
Total Assets 26.28 22.93 19.39
Reserves & Surplus 1.65 3.76 2.08
Borrowings 11.03 11.13 10.83
EBITDA Margin (%) 20.79
PAT Margin (%) 10.10
RoE
35.84
RoCE
38.46
RoNW
27.38
PAT Margin
10.10
EBITDA Margin
20.79
Debt/Equity
1.50
Issue Structure & Shareholding
Total Shares Offered1,38,000
Net Offer to Public25,62,000 shares (agg. up to ₹11 Cr)
Reserved for Market Maker1,38,000 shares (agg. up to ₹0.5934 Cr)
Pre-Issue Promoter Holding69,00,000 shares
Post-Issue Promoter Holding96,00,000 shares
P/BV RatioN/A
RoE35.84
RoCE38.46
Debt / Equity1.50
Script CodeN/A
Registrar & Lead Managers
Book Running Lead Managers
Cumulative Capital Pvt.Ltd
GMP Disclaimer: Grey Market Premium data is unofficial and unregulated. It does not guarantee actual listing price.
IPO Subscription FAQs
How much Goldline Pharmaceutical Ltd. IPO subscribed?

Goldline Pharmaceutical Ltd. IPO is subscribed 598.69 times by May 14, 2026. Retail: 874.20x. QIB: 76.99x. NII: 1,664.45x.

Investor CategorySubscription
Qualified Institutional (QIB)76.99x
Non Institutional (NII/HNI)1,664.45x
Retail Individual874.20x
Total Subscription598.69x
What is Goldline Pharmaceutical Ltd. IPO retail subscription status?

The Goldline Pharmaceutical Ltd. IPO retail category is subscribed 874.20 times as of 14 May 2026. The retail portion is oversubscribed.

How to subscribe Goldline Pharmaceutical Ltd. IPO?

Subscribe via your broker app using ASBA or UPI. Opens 12 May 2026 and closes 14 May 2026. Min investment: ₹129,000 (1 lot = 3,000 shares). UPI mandate: 5:00 PM on 14 May 2026.

How many times Goldline Pharmaceutical Ltd. IPO subscribed?

The Goldline Pharmaceutical Ltd. IPO subscribed 598.69x overall. QIB: 76.99x, NII: 1,664.45x, Retail: 874.20x. Applications: from NSE/BSE.

How to check Goldline Pharmaceutical Ltd. IPO allotment?

Check allotment on the registrar website (Bigshare Services Pvt.Ltd) at https://ipo.bigshareonline.com/IPO_Status.html. Enter your PAN, application number or DP/Client ID. Allotment date: 15 May 2026. Refunds: on 18 May 2026.

When Goldline Pharmaceutical Ltd. IPO will be listed?

The Goldline Pharmaceutical Ltd. IPO listing date is 19 May 2026, Tuesday. Listed on: BSE SME. Issue price: ₹43. Estimated listing: ₹69. GMP: +₹26.

When Goldline Pharmaceutical Ltd. IPO close?

The Goldline Pharmaceutical Ltd. IPO closes on 14 May 2026, Thursday. UPI mandate: 5:00 PM on 14 May 2026. Allotment: 15 May 2026. Listing: 19 May 2026.